Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Cardiac and Laboratory Findings in Patients With Systemic Lupus Erythematosus

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03179046
Recruitment Status : Recruiting
First Posted : June 7, 2017
Last Update Posted : March 7, 2019
Sponsor:
Information provided by (Responsible Party):
Maha Sayed Ibrahim Abdelrahman, Assiut University

Brief Summary:
This study is designed to investigate the association of the clinical and laboratory parameters or data with the cardiac structural and functional abnormalities in systemic lupus erythematosus(SLE). Patients with at least four ACR classification criteria for SLE and stable clinical condition (no need for immunosuppressive therapy intensification, i.e. current immunosuppressive drug dose increase or introduction of an additional immunosuppressive drug within last 3 months) will be included in the study. Study procedures will include clinical evaluation, lab tests including blood counts, liver and kidney functions and antibodies levels such as ANA, antiphospholipid antibodies, anti-ds DNA as well as inflammatory markers such as sedimentation rates. Also evaluation of cardiac status by cardiologist examination echocardiography and gadolinium enhanced cardiac MRI. Next, correlation between cardiac abnormalities and laboratory changes will be statistically analyzed.

Condition or disease Intervention/treatment
Systemic Lupus Erythematosus Diagnostic Test: Laboratory tests and cardiac imaging

Detailed Description:
  • Subject recruitment and obtaining consent Study subjects (SLE patients) will be recruited from patients attending outpatient clinic and inpatients of the Rheumatology and Rehabilitation Department, Faculty of Medicine, Assiut University. Written informed consent form will be obtained from each patient.
  • Baseline evaluation:

    1. All SLE patients selected for the study will fulfill the ACR criteria for the diagnosis of SLE .
    2. Thorough clinical history and examination will be performed to all SLE patients. Pulmonary function (PFTs) test will be performed to exclude respiratory failure.
    3. Urine pregnancy test to exclude pregnancy will be performed to all SLE females' patients of the childbearing period in the study group.
  • Laboratory tests: the following tests will be performed to all study population:

    1. Complete blood count (CBC),
    2. Liver and kidney functions and measurement of protein in urine collected over 24 hours,
    3. Levels of Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP).
    4. Antinuclear antibodies (ANA) and their titer will be assessed by indirect immunofluorescence,
    5. Complement system C3 and C4 factors will be measured to determine disease activity,
    6. Serum levels of anticardiolipin (aCL) and lupus anticoagulant antibodies will be measured using ELISA.
  • Disease activity will be assessed by using SELDAI score [11].
  • Cardiac evaluation

    1. Echocardiography will be performed to evaluate structural and functional outcome measures.
    2. Cardiac MRI: Multiple consecutive MR image sections will be obtained from the apex to the base of the heart. T2 and T1 mapping will be performed. T1-weighted inversion recovery scout images will be acquired 15 min after injection of 0.2 mmol/kg of gadolinium based contrast agent. The functional and volumetric analysis will be performed to quantify ventricular volumes and functions.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 30 participants
Observational Model: Case-Only
Time Perspective: Cross-Sectional
Official Title: Association of Heart Structure and Function Abnormalities With Laboratory Findings in Patients With Systemic Lupus Erythematosus
Actual Study Start Date : April 1, 2018
Estimated Primary Completion Date : April 2019
Estimated Study Completion Date : April 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lupus


Intervention Details:
  • Diagnostic Test: Laboratory tests and cardiac imaging
    Laboratory tests (blood count, liver and kidney functions, antibodies, acute phase reactants), Echocardiography and gadolinium enhanced cardiac MRI


Primary Outcome Measures :
  1. Correlation between echocardiographic parameters and the presence of autoantibodies as well as the concentration of CRP and complement C3 and C4 components. [ Time Frame: 1year ]
    Correlation between echocardiographic parameters (left ventricle diastolic and systolic dimensions, its ejection fraction, thickness of the walls in diastole, left atrium diameter, right ventricle diastolic diameter, ascending aorta diameter, mitral and tricuspid inflow velocity, valvular pressure gradients, regurgitation assessment , thickness of pericardium and the presence of pericardial effusion) and the presence of autoantibodies as well as the concentration of CRP and complement C3 and C4 components.

  2. The presence of subclinical myocarditis, assessment of coronary blood flow, left and right ventricle as shown by cardiac MRI and its correlation with autoantibodies. [ Time Frame: 1 year ]

    The presence of subclinical myocarditis, assessment of coronary blood flow, left and right ventricle (including ventricular size, thickness, wall motion, and ejection fraction) as shown by cardiac MRI(Multiple consecutive MR image sections will be obtained from the apex to the base of the heart. T2 and T1 mapping will be performed. T1-weighted inversion recovery scout images will be acquired 15 min after injection of 0.2 mmol/kg of gadolinium based contrast agent. The functional and volumetric analysis will be performed to quantify ventricular volumes and functions.

    ) and its correlation with autoantibodies.


  3. Correlation between cardiac abnormalities (evaluated with Echocardiography and cardiac MRI) and disease activity evaluated with SELDAI score. [ Time Frame: 1 year ]
    Correlation between cardiac abnormalities(evaluated with Echocardiography and cardiac MRI) and disease activity evaluated with SELDAI score.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
  • Patients have at least four ACR classification criteria for SLE.
  • Stable clinical condition (no need for immunosuppressive therapy intensification, i.e. current immunosuppressive drug dose increase or introduction of an additional immunosuppressive drug within last 3 months).
Criteria

Inclusion Criteria:

  • Patients have at least four ACR classification criteria for SLE.
  • Stable clinical condition (no need for immunosuppressive therapy intensification, i.e. current immunosuppressive drug dose increase or introduction of an additional immunosuppressive drug within last 3 months).

Exclusion Criteria:

  • Patients less than 18 years old
  • Clinical symptoms of heart failure.
  • Renal failure (creatinine clearance < 30 ml/ min).
  • Respiratory failure.
  • Pregnancy.
  • Patients with contraindications for MRI e.g. patients with aneurysm clips or cardiac pacemakers and patients who are sensitive to gadolinium dye.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03179046


Contacts
Layout table for location contacts
Contact: maha abdelrahman 01011212050 mahasi11@yahoo.com

Locations
Layout table for location information
Egypt
Assiut University Facultu of Medicine Recruiting
Assiut, Egypt
Contact: maha abdelrahman    01011212050    mahasi11@yahoo.com   
Sponsors and Collaborators
Assiut University

Layout table for additonal information
Responsible Party: Maha Sayed Ibrahim Abdelrahman, Assistant lecturer, Assiut University
ClinicalTrials.gov Identifier: NCT03179046     History of Changes
Other Study ID Numbers: 17200078
First Posted: June 7, 2017    Key Record Dates
Last Update Posted: March 7, 2019
Last Verified: March 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Lupus Erythematosus, Systemic
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases